	US 11,666,635 B2
	Stable liquid gonadotropin formulation
Helen Ulrika Sjögren, Lund (SE); and Charlotte Hojer-Pedersen, Viby Sjaelland (DK)
Assigned to Ferring B.V., Hoofddorp (NL)
Filed by Ferring B.V., Hoofddorp (NL)
Filed on Sep. 14, 2020, as Appl. No. 17/20,279.
Application 17/020,279 is a continuation of application No. 16/079,428, granted, now 10,792,334, previously published as PCT/EP2017/054325, filed on Feb. 24, 2017.
Claims priority of application No. 1603280 (GB), filed on Feb. 24, 2016.
Prior Publication US 2021/0236600 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/24 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 9/08 (2006.01); A61P 15/08 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01)

CPC A61K 38/24 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61P 15/08 (2018.01)]

22 Claims

1. A liquid pharmaceutical formulation comprising a gonadotropin, 50-160 mM arginine, and 0.05-1.5 mg/mL methionine, wherein the formulation does not additionally comprise a buffer, and wherein the pH of the formulation is between 6.0 and 7.5.